Update time：2021-10-11 11:16Tag: new mass
The U.K. technology company said that this technology can analyze small and large molecules simultaneously and end-user manufacturing processes will be interfaced in the second half of 2021.
The company said that this technology allows for the constant monitoring of production processes to ensure a high-quality biological production input.
”In just a short time we have demonstrated and delivered an efficient automated production scaling methodology to fast-track drugs and vaccines to market, at a lower cost of production and without manual human intervention, whilst maintaining consistent high quality,” Chief Executive Glenn Tracey said.
Write to Anthony O. Goriainoff at firstname.lastname@example.org